These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 10546006)

  • 1. Effect of simvastatin treatment on cardiovascular resource utilization in impaired fasting glucose and diabetes. Findings from the Scandinavian Simvastatin Survival Study.
    Herman WH; Alexander CM; Cook JR; Boccuzzi SJ; Musliner TA; Pedersen TR; Kjekshus J; Pyörälä K
    Diabetes Care; 1999 Nov; 22(11):1771-8. PubMed ID: 10546006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study.
    Haffner SM; Alexander CM; Cook TJ; Boccuzzi SJ; Musliner TA; Pedersen TR; Kjekshus J; Pyörälä K
    Arch Intern Med; 1999 Dec 13-27; 159(22):2661-7. PubMed ID: 10597756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the secondary prevention of cardiovascular disease: forecasting the incremental benefits of preventing coronary and cerebrovascular events.
    Grover SA; Coupal L; Paquet S; Zowall H
    Arch Intern Med; 1999 Mar; 159(6):593-600. PubMed ID: 10090116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20,536 individuals.
    Mihaylova B; Briggs A; Armitage J; Parish S; Gray A; Collins R;
    Lancet; 2005 May 21-27; 365(9473):1779-85. PubMed ID: 15910950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Analysis of cost-effectiveness of simvastatin versus atorvastatin in the secondary prevention of cardiovascular events within the Brazilian public healthcare system].
    Araujo DV; Ribeiro de Souza CP; Bahia LR; Rey HC; Dos Santos Junior B; Tura BR; Berwanger O; Buehler AM; Silva MT
    Value Health; 2011; 14(5 Suppl 1):S29-32. PubMed ID: 21839894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of high-dose atorvastatin compared with regular dose simvastatin.
    Lindgren P; Graff J; Olsson AG; Pedersen TJ; Jönsson B;
    Eur Heart J; 2007 Jun; 28(12):1448-53. PubMed ID: 17371782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20,536 people.
    ; Mihaylova B; Briggs A; Armitage J; Parish S; Gray A; Collins R
    BMJ; 2006 Dec; 333(7579):1145. PubMed ID: 17098764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statin cost-effectiveness in the United States for people at different vascular risk levels.
    Heart Protection Study Collaborative Group
    Circ Cardiovasc Qual Outcomes; 2009 Mar; 2(2):65-72. PubMed ID: 20031817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Ezetimibe on the Rate of Cardiovascular-Related Hospitalizations and Associated Costs Among Patients With a Recent Acute Coronary Syndrome: Results From the IMPROVE-IT Trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial).
    Pokharel Y; Chinnakondepalli K; Vilain K; Wang K; Mark DB; Davies G; Blazing MA; Giugliano RP; Braunwald E; Cannon CP; Cohen DJ; Magnuson EA
    Circ Cardiovasc Qual Outcomes; 2017 May; 10(5):. PubMed ID: 28506979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study.
    Tominaga M; Eguchi H; Manaka H; Igarashi K; Kato T; Sekikawa A
    Diabetes Care; 1999 Jun; 22(6):920-4. PubMed ID: 10372242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular and economic outcomes after initiation of atorvastatin versus simvastatin in an employed population stratified by cardiovascular risk.
    Simpson RJ; Signorovitch J; Ramakrishnan K; Ivanova J; Birnbaum H; Kuznik A
    Am J Ther; 2011 Nov; 18(6):436-48. PubMed ID: 20802306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of atorvastatin in the prevention of cardiovascular events in diabetic patients: a French adaptation of CARDS.
    Lafuma A; Colin X; Solesse A
    Arch Cardiovasc Dis; 2008 May; 101(5):327-32. PubMed ID: 18656091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of treating hyperlipidemia in the presence of diabetes : who should be treated?
    Grover SA; Coupal L; Zowall H; Dorais M
    Circulation; 2000 Aug; 102(7):722-7. PubMed ID: 10942738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrating economic analysis into clinical trials.
    Imai K; Zhang P
    Lancet; 2005 May 21-27; 365(9473):1749-50. PubMed ID: 15910936
    [No Abstract]   [Full Text] [Related]  

  • 15. Can simvastatin improve erectile function and health-related quality of life in men aged ≥40 years with erectile dysfunction? Results of the Erectile Dysfunction and Statins Trial [ISRCTN66772971].
    Trivedi D; Kirby M; Wellsted DM; Ali S; Hackett G; O'Connor B; van Os S
    BJU Int; 2013 Feb; 111(2):324-33. PubMed ID: 22686292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S).
    Strandberg TE; Pyörälä K; Cook TJ; Wilhelmsen L; Faergeman O; Thorgeirsson G; Pedersen TR; Kjekshus J;
    Lancet; 2004 Aug 28-Sep 3; 364(9436):771-7. PubMed ID: 15337403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy and safety of ezetimibe/simvastatin combination compared with intensified lipid-lowering treatment strategies in diabetic subjects with and without metabolic syndrome.
    Jimenez JG; Rosen JB; Pirags V; Massaad R; Hanson ME; Brudi P; Triscari J
    Diabetes Obes Metab; 2013 Jun; 15(6):513-22. PubMed ID: 23279632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How cost-effective is the treatment of dyslipidemia in patients with diabetes but without cardiovascular disease?
    Grover SA; Coupal L; Zowall H; Alexander CM; Weiss TW; Gomes DR
    Diabetes Care; 2001 Jan; 24(1):45-50. PubMed ID: 11194239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. On the hypothetical universal use of statins in primary prevention: an observational analysis on low-risk patients and economic consequences of a potential wide prescription rate.
    Macchia A; Mariani J; Romero M; Robusto F; Lepore V; Dettorre A; Tognoni G
    Eur J Clin Pharmacol; 2015 Apr; 71(4):449-59. PubMed ID: 25666028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of diagnostic cluster methodology for therapeutic costing and drug surveillance of HMG-CoA reductase-inhibitor therapy.
    Bottorff MB; Yenkowsky JP; Cave DG
    Clin Ther; 1999 Jan; 21(1):218-35. PubMed ID: 10090437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.